An Open-Label, Non-Randomized Study of Safety, Tolerability and Pharmacokinetics of Intravenous CXA-10 Emulsion in Subjects With Stage 3 and 4 Chronic Kidney Injury
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2018
Price : $35 *
At a glance
- Drugs CXA 10 (Primary)
- Indications Renal failure
- Focus Adverse reactions
- Sponsors Complexa
- 12 Nov 2015 According to Complexa media release, results were presented at the American Society of Nephrology's Kidney Week 2015.
- 12 Nov 2015 According to Complexa media release, status changed from recruiting to completed.
- 03 Oct 2014 New trial record